REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:53 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Minoxidil
Disease:  Androgenetic Alopecia
Target:   ATP-sensitive potassium channel

EVIDENCE GRADE: Approved
Confidence Score: 88%
Evidence Level: Level 1 (RCT + regulatory approval)
Trial Phase: Phase III

MECHANISM
---------
Topical minoxidil prolongs anagen phase; VEGF upregulation may promote follicular perfusion.

OUTCOMES
--------
Increased hair count and patient-reported improvement vs vehicle.

AI SUMMARY (generated March 15, 2026)
-----------
Topical minoxidil is FDA-approved for androgenetic alopecia, repurposed from oral antihypertensive hypertrichosis observations. Efficacy is modest but well-established in RCTs.

KNOWN RISKS
-----------
• Fluid retention and tachycardia (oral)
• Scalp irritation (topical)
• Hypertrichosis at unintended sites
• Pericardial effusion (oral, rare)

CITATIONS
---------
[PUBMED] 9777765: Topical minoxidil for androgenetic alopecia
  https://pubmed.ncbi.nlm.nih.gov/9777765/

[CLINICALTRIALS] NCT00191501: Minoxidil topical solution trial
  https://clinicaltrials.gov/study/NCT00191501

[FDA] 020834: Rogaine (minoxidil)
  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020834

PUBMED IDs: 9777765
CLINICAL TRIAL IDs: NCT00191501

LAST VERIFIED: June 27, 2026
LAST UPDATED:  June 27, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode